Quest Diagnostics Incorporated
$258.28-$0.81 (-0.3%)
Last close · Data as of Nov 20, 2026
- Market cap
- $21.7B
- P/E
- 21.9x
- EV / EBITDA
- 12.9x
- Revenue
- $11.0B
- Net margin
- 9.0%
- ROCE
- 11.2%
Price chart
Technical chartScreen technicals →+37.7% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +8.9%
- 3M
- +7.0%
- 6M
- +33.3%
- 1Y
- +37.7%
- 5Y
- +74.0%
52-week range
Day change -$0.81 (-0.3%) from $259 to $258 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in DGX, bought on each weekday since 2021.
News & filings
What Quest Diagnostics Incorporated filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthOperating profit was 5.8 times interest costs.
Concerns
No concern stands out for this company on the data on file.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Read moreShow less
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
- Sector
- Healthcare
- Shares outstanding
- 111.8M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $21.7B
- P/E
- 21.9x
- P/B
- 3.0x
- EV / EBITDA
- 12.9x
- EV / Sales
- 2.5x
- P/S
- 2.0x
- 52-week high
- $262.21
- 52-week low
- $173.49
Profitability
- Operating margin
- 14.1%
- Net margin
- 9.0%
- EBITDA margin
- 19.6%
- ROE
- 13.8%
- ROCE
- 11.2%
- ROA
- 6.1%
- Asset turnover
- 0.68
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $11.0B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 11.8%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 3.7%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 13.9%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $1.4B
Solvency
- Current ratio
- 1.04
- Debt / Equity
- 0.92
- Debt / Assets
- 0.41
- CFO / Net profit
- 1.90
- Cash / Market cap
- 1.9%
Where the revenue went
Of every $100 of FY2025 revenue, $9 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $7.4B |
| Revenue | Gross profit | $3.7B |
| Gross profit | Selling, general and administrative | $2.0B |
| Gross profit | Other operating expenses | $142.0M |
| Gross profit | Operating income | $1.6B |
| Operating income | Pretax income | $1.3B |
| Operating income | Interest and other expense | $238.0M |
| Pretax income | Tax and other | $326.0M |
| Pretax income | Net income | $992.0M |
Revenue and net profit
Revenue grew 11.8% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $9.9B | $946.0M |
| FY2023 | $9.3B | $854.0M |
| FY2024 | $9.9B | $871.0M |
| FY2025 | $11.0B | $992.0M |
Cash flows
FY2025: $1.9B from operations, $1.4B free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $1.7B | $1.3B |
| FY2023 | $1.3B | $864.0M |
| FY2024 | $1.3B | $909.0M |
| FY2025 | $1.9B | $1.4B |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $11.0B+11.8%1Y
- EBITDA
- $2.2B+14.3%1Y
- Net profit
- $992.0M+13.9%1Y
- Cash from operations
- $1.9B+41.4%1Y
- Free cash flow
- $1.4B+49.5%1Y
- Revenue CAGR, 3Y
- 3.7%
- Net profit CAGR, 3Y
- 1.6%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $11.0B | $2.2B | $992.0M | $1.4B | 13.8% | +11.8% | +13.9% |
Monthly returns
Month-by-month returns of DGX across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $16.2B |
| Current assets | $2.4B |
| Non-current assets | — |
| Liabilities | $8.9B |
| Current liabilities | $2.3B |
| Non-current liabilities | $6.7B |
| Equity | $7.3B |
| Paid-in capital | $2.4B |
| Retained earnings | $10.0B |
| Treasury stock | $5.2B |
| Minority interest | $116.0M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; DGX highlighted.
P/E against peers
DGX trades at 21.9x earnings against a peer median of 24.4x (a 10% discount).
Not shown (no positive earnings and no EV / Sales): Insmed Incorporated, Moderna, Inc., Viatris Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Quest Diagnostics IncorporatedDGXthis companyP/E ↓ discount | $21.7B | 21.9x | 3.0x | 13.8% | 12.9x |
| Mettler-Toledo International Inc.MTD | $23.9B | 27.4x | — | -3676.8% | 20.9x |
| Insmed IncorporatedINSM | $22.7B | -17.8x | 30.8x | -172.8% | — |
| West Pharmaceutical Services, Inc.WST | $22.4B | 45.4x | 7.1x | 15.5% | 28.4x |
| Labcorp Holdings Inc.LH | $21.4B | 24.4x | 2.5x | 10.2% | 13.6x |
| STERIS plcSTE | $20.7B | 26.5x | 2.9x | 10.9% | 14.0x |
| Moderna, Inc.MRNA | $20.5B | -7.3x | 2.4x | -32.6% | -7.5x |
| Incyte CorporationINCY | $20.2B | 15.7x | 3.9x | 24.9% | 9.8x |
| Viatris Inc.VTRS | $18.5B | — | 1.3x | -23.9% | — |
| Peer median | — | 24.4x | 2.9x | -6.9% | 13.8x |
Year-to-date ROI
DGX since 1 January, against earlier years.
Historical volatility
DGX's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 14.4% |
| FY2023 | 13.6% |
| FY2024 | 13.6% |
| FY2025 | 14.1% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $11.0B |
| Cost of revenueCost Of Revenue | $7.4B |
| Gross profitGross Profit | $3.7B |
| Operating expensesOperating Expense | $2.1B |
| Selling, general and administrativeSelling General And Administration | $2.0B |
| Other operating expensesOther Operating Expenses | -$12.0M |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $154.0M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $154.0M |
| Amortization | $154.0M |
| Amortisation of intangiblesAmortization Of Intangibles Income Statement | $154.0M |
| Total expensesTotal Expenses | $9.5B |
| Operating incomeOperating Income | $1.6B |
| Interest and other | |
| Pretax incomePretax Income | $1.3B |
| TaxTax Provision | $314.0M |
| Net incomeNet Income | $992.0M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $16.2B |
| Current assetsCurrent Assets | $2.4B |
| Non-current assets | |
| LiabilitiesTotal Liabilities Net Minority Interest | $8.9B |
| Current liabilitiesCurrent Liabilities | $2.3B |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $6.7B |
| EquityTotal Equity Gross Minority Interest | $7.3B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $1.9B |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $1.9B |
| Net income, continuing operationsNet Income From Continuing Operations | $1.0B |
| Depreciation and amortisationDepreciation And Amortization | $570.0M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $570.0M |
| Depreciation | $416.0M |
| Amortization cash flowAmortization Cash Flow | $154.0M |
| Amortization of intangiblesAmortization Of Intangibles | $154.0M |
| Stock-based compensationStock Based Compensation | $88.0M |
| Deferred taxDeferred Tax | $105.0M |
| Deferred income taxDeferred Income Tax | $105.0M |
| Operating gains and lossesOperating Gains Losses | — |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | — |
| Gain loss on sale of businessGain Loss On Sale Of Business | — |
| Provision and write off of assetsProvisionand Write Offof Assets | $3.0M |
| Change in working capitalChange In Working Capital | $50.0M |
| Other non-cash itemsOther Non Cash Items | $24.0M |
| Investing cash flowInvesting Cash Flow | -$631.0M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$631.0M |
| Capital expenditureCapital Expenditure | -$527.0M |
| Capital expenditure (reported)Capital Expenditure Reported | -$527.0M |
| Sale of PP&ESale Of PPE | — |
| Net PP&E purchases and salesNet PPE Purchase And Sale | — |
| AcquisitionsPurchase Of Business | -$101.0M |
| DisposalsSale Of Business | — |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$101.0M |
| Purchase of investmentsPurchase Of Investment | — |
| Sale of investmentsSale Of Investment | — |
| Net investment purchases and salesNet Investment Purchase And Sale | — |
| Other investing changesNet Other Investing Changes | -$3.0M |
| Financing cash flowFinancing Cash Flow | -$1.4B |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$1.4B |
| Debt issuedIssuance Of Debt | $410.0M |
| Debt repaidRepayment Of Debt | -$1.0B |
| Net debt issuedNet Issuance Payments Of Debt | -$602.0M |
| Long-term debt issuedLong Term Debt Issuance | $410.0M |
| Long-term debt repaidLong Term Debt Payments | -$1.0B |
| Net long-term debt issuedNet Long Term Debt Issuance | -$602.0M |
| Net common stock issuedNet Common Stock Issuance | -$450.0M |
| Common stock repurchasedCommon Stock Payments | -$450.0M |
| Share buybacksRepurchase Of Capital Stock | -$450.0M |
| Stock options exercisedProceeds From Stock Option Exercised | $79.0M |
| Dividends paidCash Dividends Paid | -$353.0M |
| Common dividends paidCommon Stock Dividend Paid | -$353.0M |
| Other financing chargesNet Other Financing Charges | -$62.0M |
| Change in cashChanges In Cash | -$133.0M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 400.0% |
| Cash at the start of the yearBeginning Cash Position | $549.0M |
| Cash at the end of the yearEnd Cash Position | $420.0M |
| Free cash flowFree Cash Flow | $1.4B |
| Supplemental |
Learn while you research
Academy chapters picked for Quest Diagnostics Incorporated and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read